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ABSTRACT
Wilms’ tumor is one of the most common solid tumors
of children. The protein product of the tumor-suppressor
gene, Wilms’ tumor 1 (WT-1), binds to the same DNA
sequences as the protein product of the early growth re-
sponse 1 (EGR-1) gene. There is experimental evidence that
EGR-1 is involved in controlling cell growth. The expression
of both genes in Wilms’ tumor was studied by others, mainly
at the mRNA level. The present study evaluates the prog-
nostic value of WT-1 and EGR-1 in 61 Wilms’ tumors of
chemotherapeutically treated patients at the protein level,
using an immunohistochemical approach. WT-1 was ex-
pressed in normal kidney tissues and in the blastemal and
epithelial component of Wilms’ tumor, whereas stromal
tissue was negative. EGR-1 was expressed in normal kidney
tissues and in the three main cell types of Wilms’ tumor. In
59 and 56% of Wilms’ tumor, the blastemal cells stained for
WT-1 and EGR-1, respectively. The blastemal expression of
WT-1 and EGR-1 and the epithelial expression of WT-1
were statistically significantly correlated with clinical stage.
WT-1 immunoreactivity correlated with EGR-1 expression.
Univariate analysis showed that blastemal WT-1 and EGR-1
expression were indicative for clinical progression and tu-
mor-specific survival, whereas epithelial staining was of no
prognostic value. Multivariate analysis showed that blast-
emal WT-1 expression is an independent prognostic marker
for clinical progression other than stage. We conclude that a
relationship exists between WT-1 and EGR-1 expression in
clinical nephroblastomas. Blastemal WT-1 and EGR-1 ex-
pression is related to prognosis.
INTRODUCTION
Wilms’ tumor is a pediatric malignancy of the kidney and
one of the most common solid tumors in children (1). At
present, the prediction of outcome is based mainly on histology
and stage at the time of resection (2). Despite remarkable
advances in elucidating molecular events involved in the patho-
genesis of Wilms’ tumor, an independent prognosticator has not
been identified as yet (3).
The genetic basis of this tumor is highly complex, and
several loci have been shown to be associated with tumor
formation. The WT-12 gene (tumor suppressor gene) is localized
at human chromosome 11p13. Estimates of the frequency of
WT-1 mutations are sometimes difficult to interpret because of
varying methods of detection. The percentage of Wilms’ tumors
that have been shown to contain homozygous or heterozygous
WT-1 mutations is relatively low, however, and may be ,25%
and perhaps as little as 5% (4, 5). The WT-1 protein has been
implicated in many processes, such as proliferation, differenti-
ation, and apoptosis (6). Comparison of the amino acid sequence
of the zinc fingers of WT-1 with the amino acid sequences of
other zinc finger proteins revealed a high degree of similarity of
WT-1 and early growth response genes such as EGR-1 (7).
EGR-1 expression is induced during the G0-G1 transition of the
cell cycle in a variety of cell lines upon mitogenic stimulation,
suggesting that EGR-1 is involved in controlling cellular pro-
liferation. However, the effect of EGR-1 on cell growth may
also be cell type specific (8).
The results of a number of transient transfection studies
demonstrated that WT-1 represses transcription of promoters
responsive to EGR-1 (9, 10). These results suggest that there
may be a reciprocal expression between these two proteins:
WT-1 may act as an antagonist of EGR-1 or may be a tissue-
specific factor that is involved in maintaining a particular dif-
ferentiated phenotype. The balance in the levels of EGR-1 and
WT-1 proteins in the nucleus may therefore be critical, and
inactivation of WT-1 could result in the onset of neoplasia. In
the present study, the immunohistochemical expression patterns
of WT-1 and EGR-1 were studied in Wilms’ tumor tissues, and
the prognostic value was determined in patients treated by
preoperative chemotherapy and radical nephrectomy.
MATERIALS AND METHODS
Patients. During the period 1987–1999, 61 patients with
nephroblastoma were treated by neo-adjuvant chemotherapy
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and, subsequently, with tumor nephrectomy. After treatment,
the patients were followed regularly, and all data concerning
diagnosis, treatment, and follow-up were stored in a database.
Clinical progression was defined as histologically or cytologi-
cally proven local recurrence or the appearance of distant me-
tastases. Tumor death was defined as death as a result of the
direct effect of metastases.
Sample Selection. All nephrectomy specimens were
fixed in 10% buffered formalin and embedded in paraffin. The
H&E-stained slides were reviewed by an experienced pediatric
pathologist (J. C. D. H.) to assess the stage according to the
TNM classification (11). Among the tissue blocks available for
individual patients, tumor samples containing the three different
cell types of Wilms’ tumor were selected. In addition, adjacent
normal kidney tissue was taken from each patient.
Immunohistochemistry. The following primary antibod-
ies were used: F-6, a mouse monoclonal antibody against WT-1;
and 588, rabbit polyclonal antibody against EGR-1, both from
Santa Cruz Biotechnology (Santa Cruz, CA). The specificities and
characteristics of these antibodies have been published elsewhere
(7, 8). The peroxidase-antiperoxidase technique was used. Serial
sections (5 mm) from all samples were mounted on 3-aminopro-
pyle-trietoxysilane (Sigma Co., St. Louis, MO)-coated glass slides,
which were incubated overnight, in a 60°C incubator. After dew-
axing in fresh xylene for 10 min and rehydration in 100% methanol
for 10 min, the sections were rinsed in methanol containing 3%
Fig. 1 WT-1 and EGR-1 staining of normal kidney and clinical Wilms’ tumor tissues. Glomerular visceral epithelium of normal kidney tissue
showed positive nuclear staining of WT-1 (A) and tubular cytoplasmic staining of EGR-1 (B). Nuclear WT-1 expression was found in Wilms’ tumor
blastema (C) and epithelium (E), whereas cytoplasmic expression of EGR-1 was found in the blastemal (D) and epithelial (F) compartments. Arrows
indicate stained blastemal cells in C and D, respectively. Slides were counterstained with hematoxylin (3400).
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hydrogen peroxide for 20 min to block endogenous peroxidase
activity. The slides then were rinsed with distilled water. To en-
hance antigen exposure, the slides were microwaved at 700 W in
0.1 M citrate buffer (pH 6.0) for 15 min. After being cooled and
rinsed with PBS, the slides were placed in a Sequenza immuno-
staining system (Shandon, Uncorn, United Kingdom). Sections
were incubated with 10% normal rabbit serum if the monoclonal
antibody was to be used or normal goat serum if the polyclonal
antibody was to be used (DAKO A/S, Glostrup, Denmark). Slides
were incubated in PBS-5% BSA for 15 min and subsequently
overnight with the primary antibody at 4°C. The antibodies were
diluted in PBS-5% BSA at 1:100 for WT-1 and 1:300 for EGR-1.
Subsequently, the slides were rinsed with PBS-0.1% Tween, incu-
bated for 30 min with rabbit antimouse antibody for the mono-
clonal antibody or goat antirabbit antibody for the polyclonal an-
tibody (DAKO), and then rinsed with PBS containing 0.1% Tween.
The peroxidase-antiperoxidase complex (PAP; DAKO) was di-
luted in PBS-5% BSA at 1:300, incubated for 30 min, and then
rinsed with PBS. The antigen-antibody complex was visualized
with diaminobenzidine tetrahydrochloride dihydrate (Fluka, Neu-
Ulm, Germany) as chromogen. The sections were lightly counter-
stained with hematoxylin. Negative controls were included by
replacing the primary antibody by PBS- 5% BSA. Normal kidney
tissue, which was present in all clinical specimens, served as
positive control.
Immunostaining Analysis (Quantification). The slides
were examined at 325 magnification without knowledge of the
clinical outcome of the patients. Semiquantitative evaluation
was performed by one of the authors (T. H. V. d. K.). The
percentage of WT-1- and EGR-1-positive cells in a particular
area was scored semiquantitatively as ,10, 10–25, 25–50, and
.50%. The specimens were regarded as positive when the
percentage of positive cells was .10%. In addition, the amount
of blastema was estimated by counting the number of low-
power magnification fields of blastema.
Statistical Analysis. Statistical analysis was performed
using the SPSS 9 software package. The association between
WT-1 and EGR-1 expression and clinico-pathological features
was analyzed using the Pearson x2 test. For analysis of survival
data, Kaplan-Meier curves were constructed and the log-rank
test for trend was performed. Multivariate analysis was per-
formed using Cox’s proportional hazards model, with P , 0.05
considered statistically significant.
Protein Extraction and Western Blot. To confirm the
WT-1 and EGR-1 immunohistochemical data, Western analysis
was performed with tissues from Wilms’ tumor xenografts. Six
different xenograft tissues were analyzed in total. Tissues 1–3
(see Fig. 6) originated from transplants of three individual
patients, resulting in xenografts WT-7, WT-9, and WT-11,
respectively, whereas tissues 4–6 (WT-15, WT-15LN, and WT-
16) were from one individual patient, being specimens of a
primary tumor in the right kidney (WT-15), lymph node metas-
tasis (WT-15LN), and a primary tumor in the left kidney (WT-
16), respectively. Morphologically, all six tissues contained the
blastemal and stromal component, whereas in tissues 1 and 3,
epithelial cells were also present.
Frozen tissues were crushed in a liquid nitrogen-chilled metal
cylinder. The tissue homogenates were transferred to a lysis buffer
consisting of 10 mM Tris (pH 7.4), 150 mM NaCl (Sigma), 1%
Triton X-100 (Merck, Darmstadt, Germany), 1% deoxycholate
(Sigma), 0.1% SDS (Life Technologies), 5 mM EDTA (Merck),
and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM
aprotinin, 50 mg/liter leupeptin, 1 mM benzamidine, and 1 mg/liter
pepstatin; all from Sigma). The samples were spun at 35,000 3 g
at 4°C for 10 min. The protein content of the supernatant was
measured photometrically using the Bio-Rad, protein assay (Bio-
Rad, Munich, Germany). The proteins were transferred to a SDS-
Table 1 Relationship between pT stage and blastemal expression
Data are presented as n, with percentages in parentheses.
Score
WT-1a EGR-1a
T1 T2 T3 T1 T2 T3
,10% 4 (7%) 11 (18%) 10 (16%) 14 (23%) 10 (16%) 3 (5%)
10–25% 4 (7%) 2 (3%) 1 (2%) 4 (7%)
25–50% 13 (21%) 5 (8%) 10 (16%) 2 (3%) 5 (8%) 4 (7%)
.50% 2 (3%) 5 (8%) 4 (7%) 9 (15%)
a P , 0.05 (Pearson x2 test).
Table 2 Relationship between pT stage and epithelial expression
Data are presented as n, with percentages in parentheses.
Score
WT-1a EGR-1
T1 T2 T3 T1 T2 T3
,10% 5 (8%) 8 (13%) 13 (21%) 3 (5%) 2 (3%) 3 (5%)
10–25% 8 (13%) 8 (13%) 5 (8%) 4 (7%) 6 (10%) 7 (12%)
25–50% 8 (13%) 2 (3%) 1 (2%) 10 (16%) 8 (13%) 9 (15%)
.50% 2 (3%) 1 (2%) 4 (7%) 4 (7%) 1 (2%)
a P , 0.05 (Pearson x2 test).
Table 3 Relationship between WT-1 and EGR-1 blastemal
expression
Data are presented as n, with percentages in parentheses.
Score
EGR-1a
,10% 10–25% 25–50% .50%
,10% 14 (23%) 3 (5%) 3 (5%) 5 (8%)
WT-1a 10–25% 2 (3%) 4 (7%)
25–50% 10 (16%) 2 (3%) 3 (5%) 13 (21%)
.50% 1 (2%) 1 (2%)
a P , 0.05 (Pearson x2 test).
Table 4 Univariate analysis of prognostic markers
Variable
Outcome parameter
Blastema Epithelium
Clinical
progression
Tumor-
specific
survival
Clinical
progression
Tumor-
specific
survival
x2 Pa x2 Pa x2 Pa x2 Pa
WT-1 9.07 0.003 5.3 0.02 0.64 0.42 0.04 0.85
EGR-1 7.24 0.007 4.23 0.04 0.41 0.52 0.03 0.86
a Log-rank test for trend.
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polyacrylamide gel, and electrophoresis was performed in 103
diluted tray buffer for 2 h. The gel was blotted to a 0.45 mm
cellulose nitrate membrane (Schleicher & Schuell, Dassel, Germa-
ny). Prestained markers were used as size standards (Novex, San
Diego, CA). The immunoblot was blocked for 1 h with 5% dry
milk (Sigma) in 0.1% Tween 20 (Sigma). The antibodies were
diluted 1:1000 in 5% dry milk and were applied overnight at 4°C.
After rinsing with PBS-0.1% Tween, the blot was incubated with
horseradish peroxidase-labeled goat antirabbit antibody (1:2000;
DAKO) for 1 h. Subsequently, the blot was incubated for 1 min
with a 1:1 mixture of luminol and oxidizing reagent (Chemilumi-
nescence kit; DuPont NEN, Boston, MA). Excess reagent was
removed by placing the blot on a piece of Whatman paper. Finally,
the antibodies were visualized by exposure of the blot to an X-ray
film for 30 s.
RESULTS
Clinicopathological Findings. The T-stage distribution
was T1 in 21, T2 in 20, and T3 in 20 patients. Clinical progres-
sion occurred in 14 patients (23%). Twenty-five patients (41%)
had large amounts of blastema. The patient distribution was 29
(48%) females and 32 (53%) males. The mean overall follow-up
period was 5.7 years, and the mean age at operation was 4.2
years. Eight patients (13%) died from their tumors. At the end of
the follow-up period, 53 patients were alive.
WT-1 Expression in Wilms’ Tumor Tissues. WT-1
immunohistochemistry of normal kidney showed a very intense
nuclear staining of glomerular visceral epithelial cells but faint
staining of the tubules (Fig. 1A). WT-1 immunoreactive blast-
emal and epithelial cells were found in 59 and 57% of patients,
respectively, whereas no expression was found in the stromal
component. Immunostaining was localized in the nucleus (Fig.
1, C and E). A statistically significant correlation was found
between WT-1 protein and pathological stage, both for blastema
and epithelium (Tables 1 and 2). There was variability in the
intensity of WT-1 staining in the same component and among
the tumors having the same stage. Epithelial differentiation in
tumors was accompanied by clear WT-1 expression (Fig. 1E).
EGR-1 Expression in Wilms’ Tumor Tissues. EGR-1
immunohistochemistry of normal kidney showed a very intense
cytoplasmic staining of proximal and distal convoluted tubules,
but faint staining of the glomeruli (Fig. 1B). EGR-1 immuno-
reactivity was found in the blastemal, epithelial, and stromal
components of nephroblastoma tumors. EGR-1-immunoreactive
Fig. 2 Kaplan-Meier curves show a significant relationship between
blastemal WT-1 expression and clinical progression (A) and survival
(B). Censored patients are indicated by tic marks along their lines. The
end of the follow-up of group .50% is indicated by an 3. Numbers of
patients per group are shown.
Fig. 3 Kaplan-Meier curves show a significant relationship between
blastemal EGR-1 expression and clinical progression (A) and survival
(B). Censored patients are indicated by tic marks along their lines.
Numbers of patients per group are shown.
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blastema and epithelium were found in 56 and 87% of patients,
respectively. Immunostaining was cytoplasmic (Fig. 1, D and
F). The nephroblastoma sections showed intense expression of
the epithelium with little expression in the stromal components
(Fig. 1F). In contrast to WT-1, EGR-1 expression was more
widely distributed and more intense. The blastemal expression
of EGR-1 protein correlated with the pathological stage (Table
1). A statistically significant correlation was found between
blastemal WT-1 and EGR-1 expression (Table 3).
Prognostic Value of WT-1 and EGR-1 Molecules.
Univariate analysis using the log-rank test for trend showed a
prognostic value of blastemal WT-1 and EGR-1 expression for
clinical progression and tumor-related death (Table 4; Figs. 2
and 3). The epithelial expression of EGR-1 and WT-1 did not
show any prognostic value (Table 4; Figs. 4 and 5). To test
whether WT-1 and EGR-1 have any prognostic impact, a mul-
tivariate Cox’s regression analysis was done that included the
parameters pT stage and WT-1 and EGR-1 expression. The
parameters that were not dichotomic were dichotomized as
follows: pT1–2 versus pT3; and immunoreactive score ,10%
versus .10%. In that analysis, blastemal WT-1 could be iden-
tified as an independent prognostic marker for clinical progres-
sion other than stage (Table 5). Regarding the amount of blas-
tema, no prognostic value was found (data not shown).
Immunoblot Analysis. Immunoblot analysis of tissue ly-
sates of a panel of human Wilms’ tumor xenografts identified the
specificity of the antibodies for detection of WT-1 and EGR-1
proteins (Fig. 6). Morphologically, all six tissues contained blast-
emal and stromal components, whereas in tissues 1 and 3, epithelial
cells were also present. WT-1 was detected as a single band
corresponding to a molecular size of 52 kDa, whereas EGR-1 was
detected as a single 80-kDa band. Among this relatively small
group of tissues, heterogeneous patterns of WT-1 and EGR-1
expression were found. As expected, the majority of tissues showed
expression of WT-1, although it is remarkable that two tissues were
devoid of any WT-1 protein. Interestingly enough, both of these
tumors had relatively low EGR-1 expression. Clearly, there is no
correlation between the expression of the proteins and the morpho-
logical characteristics of the tissues.
DISCUSSION
The interaction of the related proteins WT-1 and EGR-1
has been studied during recent years. The expression of both
genes in Wilms’ tumor was examined by others mainly at the
mRNA level and was compared with clinical, histological, and
Fig. 4 Kaplan-Meier curves show a nonsignificant relationship be-
tween epithelial WT-1 expression and clinical progression (A) and
survival (B). Censored patients are indicated by tic marks along their
lines. The end of the follow-up of group .50% (B) is indicated by 3.
Numbers of patients per group are shown.
Fig. 5 Kaplan-Meier curves show a nonsignificant relationship be-
tween epithelial EGR-1 expression and clinical progression (A) and
survival (B). Censored patients are indicated by tic marks along their
lines. Numbers of patients per group are shown.
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molecular features (12–14). The present study was carried out to
investigate whether the expression of WT-1 and EGR-1 at the
protein level has a prognostic value in specimens of clinical
nephroblastoma, using paraffin-embedded tissue sections. All of
the patients received chemotherapy before nephrectomy. In the
present study, the clear expression of both WT-1 and EGR-1 in
normal kidney suggests that the interaction of WT-1 with
EGR-1 occurs well after the inductive events of the ureteral
epithelial and metanephric blastema (15). Because normal kid-
ney tissue was present in almost all sections, this could serve as
an internal control for the immunostaining procedure.
WT-1 expression is restricted to certain cell types and to a
specific stage of differentiation. Thus, the level of WT-1 expression
in neoplasia would be expected to correlate with the relative
amount of the specific cell type present. Tumors that exhibit pri-
marily blastemal and epithelial differentiation show higher levels of
WT-1 expression than those in which stroma is predominantly
present (16, 17). In our present study, no correlation was found
between the amount of blastema and prognosis. There was some
heterogeneity in the intensity of signals both between cases and in
tumors of similar stage. Variability in the intensity of immuno-
staining may be explained by the wide variation in the levels of
WT-1 transcripts that has been noted in Wilms’ tumors by Northern
blot analysis (12, 16, 18). Epithelial differentiation in tumors was
accompanied by diffuse WT-1 expression (Fig. 1E).
Stromal areas of the tumor did not express WT-1 (Fig. 1C).
The negative stromal elements included differentiated mesenchy-
mal tissue, in which adipose tissue and smooth muscle were seen.
WT-1 mRNA has not been detected in the stromal component of
Wilms’ tumors, nor have recent morphological studies demon-
strated the WT-1 protein in the stroma (19). These results suggest
that there is pathogenetic heterogeneity in Wilms’ tumors, with
stromal-predominant tumors having complete loss of expression
the gene.
WT-1 has been investigated in several human tumors other
than Wilms’ tumor. Testicular cancer has been demonstrated to
produce decreased expression of WT-1 (20, 21). On the other hand,
the WT-1 gene was found to be overexpressed in leukemia (22),
and ovarian cancer (23), in which WT-1 mRNA levels appeared to
be much higher than in normal tissues. WT-1 expression was much
lower in benign prostatic hyperplasia than in normal prostatic
tissues, but no changes were seen in prostatic adenocarcinoma (24).
In addition, altered expression of the WT-1 gene was demonstrated
in human breast cancer (25). These phenomena may be related to
the ability of WT-1 to enhance transcription of growth factors and
other genes when present in a mutated form (26) or in the presence
of modulating factors (21). A correlation exists between the levels
of WT-1 expression and poor prognosis in human hematopoietic
malignancies (27, 28).
Very recent studies, using RNA slot blot analysis, showed
expression of EGR-1 during murine nephrogenesis and overexpres-
sion in some clinical Wilms’ tumor (14, 15). In the present study,
at the protein level EGR-1 was expressed in the three components
of Wilms’ tumor (blastema, epithelium, and stroma). EGR-1 is
expressed in a high percentage of the epithelial component of
nephroblastoma specimens. Our study demonstrated a significant
increase in the expression of EGR-1 in aggressive tumors. These
observations support the hypothesis that EGR-1 plays a role in
tumor cell proliferation and/or tumor formation.
EGR-1 expression has been shown to correlate with the trans-
formed phenotype of B-lymphocytes immortalized with EBV,
causing Burkitt lymphoma (29). Low expression of EGR-1 has
been demonstrated in human breast cancer cells and tumor tissues,
as well as in human lung cancer compared with normal lung tissues
(30, 31), whereas EGR-1 is overexpressed in prostate cancer (32).
The apparent contradictory role of EGR-1 in different human
carcinomas could be attributable to the influence of the intracellular
milieu and the presence of other proteins in a certain cell type (33,
34). EGR-1 expression in nephroblastoma was found to be of
prognostic value in predicting clinical progression and tumor-spe-
cific death (Fig. 3). Increased expression of EGR-1 was associated
with an increased risk.
Multivariate analysis showed that blastemal WT-1 expres-
sion independently predicted clinical progression. Furthermore,
both WT-1 and EGR-1 bind to the same DNA response element,
suggesting the possibility of stimulation of nephroblastoma
growth via competition of EGR-1 with WT-1-binding elements
on target DNA (12, 35). Although the mechanism by which
EGR-1 counteracts the effect of WT-1 is unknown, WT-1 and
EGR-1 may have the ability to stimulate carcinogenesis in the
kidney through one or more pathways suggested above.
Our findings suggest that a relationship exists between
WT-1 and EGR-1 proteins in clinical nephroblastoma. Expres-
sion in the blastema, which rather than the epithelium is the
most malignant component of Wilms’ tumor, is predictive of
poor prognosis. Univariate analysis showed that WT-1 and
EGR-1 blastemal expression is related to prognosis. WT-1 blast-
emal expression is an independent predictor for clinical progres-
sion other than stage.
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Table 5 Results of Cox’s multi-regression analysis
Outcome parameter Variable
Hazard
ratio
95%
Confidence
limit P
Clinical progression WT-1 (blastema) 9.2 2.0–42.2 0.004
Stage 5.2 1.7–15.9 0.003
Tumor-specific
survival
WT-1 (blastema) 7.4 0.91–60.3 0.06
Fig. 6 Immunoblot analysis of WT-1 (A) and EGR-1 (B) proteins in
nephroblastoma tissues derived of six human xenograft models with
approximate indication of size markers.
4270 WT-1 and Nephroblastoma Prognosis
REFERENCES
1. Beckwith, J. B. Renal neoplasms of childhood. In: S. S. Sternberg
(ed.), Diagnostic Surgical Pathology, pp.1741–1766. New York: Raven
Press, Ltd., 1994.
2. Wiliams, B. E., Douglass, E. C., Hammond, E. E., Champion, J.,
Parham, D., and Webber, B. Relapsed Wilms’ tumor, factors affecting
survival and cure. Am. J. Clin. Oncol., 8: 324–328, 1985.
3. Wen, J. G., van Steenbrugge, G. J., Egeler, R. M., and Nijman Rien,
M. Progress of fundamental research in Wilms’ tumor. Urol. Res., 25:
223–230, 1997.
4. Slater, R. M., and Mannens, M. M. A. Cytogenetics and molecular
genetics of Wilms’ tumor of childhood. Cancer Genet. Cytogenet., 61:
111–121, 1992.
5. Mannens, M., Slater, R. M., Heyting, C., Bliek, J., de Kraker, J.,
Coad, N., de Pagter-Holthuizen, P., and Pearson, P. L. Molecular nature
of genetic changes resulting in loss of heterozygosity of chromosome 11
in Wilms’ tumours. Hum. Genet., 81: 41–48, 1988.
6. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis: its
significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013–
2026, 1994.
7. Gessler, M., Konig, A., and Bruns, G. A. The genomic organization
and expression of the WT-1 gene. Genomics, 12: 807–813, 1992.
8. Jamieson, G. A., Mayforth, R. D., Villreal, M. L., and Sukhatme,
V. P. Multiple intracellular pathways induce expression of a zinc-finger
encoding gene (EGR-1): relationship to activation of the Na/H ex-
changer. J. Cell. Physiol., 139: 262–268, 1989.
9. Sukhatme, V. P., Cao, X. M., Chang, L. C., Tsai-Morris, C. H.,
Stamenkovich, D., Ferreira, P. C., Cohen, D. R., Edwards, S. A., Shows,
T. B., Curran, T., LeBeau, M. M., and Adamson, E. D. A zinc finger-
encoding gene coregulated with c-fos during growth and differentiation
and after cellular depolarization. Cell, 53: 37–43, 1988.
10. Dey, B. R., Sukhatme, V. P., Roberts, A. B., Sporn, M. B., and
Rauscher, F. J. Repression of transforming growth factor-b1 gene by the
Wilms’ tumor suppressor WT-1 gene product. Mol. Endocrinol., 8:
595–602, 1994.
11. Delemarre, J. F., Sandstedt, B., Harms, D., Boccon-Gibood, L., and
Vujanic, G. M. The new SIOP (Stockholm) working classification of
renal tumours of childhood. International Society of Paediatric Oncol-
ogy. Med. Pediatr. Oncol., 26: 145–146, 1996.
12. Gerald, W. L., Gramling, T. S., Sens, D. A., and Garvin, A. J. Expres-
sion of the 11p13 Wilms’ tumor gene, WT-1, correlates with histologic
category of Wilms’ tumor. Am. J. Pathol., 140: 1031–1037, 1992.
13. Zhuang, Z., Merino, M. J., Vortmeyer, A. O., Bryant, B., Lash,
A. E., Wang, C., Deavers, M. T., Shelton, W. F., Kapur, S., and
Chandra, R. S. Identical genetic changes in different histologic compo-
nents of Wilms’ tumors. J. Natl. Cancer Inst., 89: 1148–1152, 1997.
14. Scharnhost, V., Menke, A. L., Attema, J., Haneveld, J. K., Riteco, N.,
van der Eb, A. J., van Steenbrugge, G. J., and Jochemsen, A. G. EGR-1
enhances tumor growth and modulates the effect of the Wilms’ tumor 1
gene products on tumorigenicity. Oncogene, 19: 791–800, 2000.
15. Rackley, R. R., Kessler, P. M., Campbell, C., and Williams,
B. R. G. In situ expression of the early growth response gene-1 during
murine nephrogenesis. J. Urol., 154: 700–705, 1995.
16. Pritchard-Jones, K., Fleming, S., Davidson, D., Bickmore, W.,
Porteous, D., Gosden, C., Bard, J., Buckler, A., Pelletier, J., Housman,
D., Van Heyningen, V., and Hastie, N. The candidate Wilms’ tumor
gene is involved in genitourinary development. Nature (Lond.), 346:
194–197, 1990.
17. Pritchard-Jones, K., and Fleming, S. Cell types expressing the
Wilms’ tumor gene (WT-1) in Wilms’ tumor: implications for tumor
histogenesis. Oncogene, 6: 2211–2220, 1991.
18. Miwa, H., Tomlinson, G. E., Timmons, C. F., Huff, V., Cohn, S. L.,
Strong, L. C., and Saunders, G. F. RNA expression of the WT1 gene in
Wilms’ tumors in relation to histology. J. Natl. Cancer Inst., 84: 181–
187, 1992.
19. Mundlos, S., Pelletier, J., Darveauu, A., Bachmann, M., Winter-
pacht, A., and Zabel, B. Nuclear localization of the protein encoded by
the Wilms’ tumor gene WT-1 in embryonic and adult tissues. Develop-
ment (Camb.), 119: 1329–1341, 1993.
20. Hastie, N. D. Wilms’ tumor gene and function. Curr. Opin. Genet.
Dev., 3: 408–413, 1993.
21. Rauscher, F. J. The WT-1 Wilms’ tumor gene product: a develop-
mentally regulated transcription factors in the kidney that functions as a
tumor suppressor. FASEB J., 7: 896–903, 1993.
22. Menssen, H. D., Renkl, H. J., Maurer, J., Schwartz, S., Reinhardt,
R., and Thiel, E. Presence of Wilms’ tumor gene (WT-1) transcripts and
the WT-1 nuclear protein in the majority of human acute leukemias.
Leukemia (Baltimore), 9: 1060–1067, 1995.
23. Bruening, W., Gros, P., Sato, T., Stanimir, J., Nakamura, Y., Housman,
D., and Pelletier, J. Analysis of the 11p13 Wilms’ tumour suppressor gene
(WT-1) in ovarian tumors. Cancer Invest., 11: 393–399, 1993.
24. Dong, G., Rajah, R., Vu, T., Hoffman, A. R., Rosenfeld, R. G.,
Roberts, C. T., Jr., Peehl, D. M., and Cohen, P. Decreased expression of
Wilms’ tumor gene WT-1 and elevated expression of insulin growth
factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal
cells from patients with benign prostatic hyperplasia. J. Clin. Endocri-
nol. Metab., 82: 2198–2203, 1997.
25. Silberstein, G. B., van Horn, K., Strickland, P., Roberts, C. T., Jr.,
and Daniel, C. W. Altered expression of the WT-1 Wilms tumor
suppressor gene in human breast cancer. Proc. Natl. Acad. Sci. USA, 94:
8132–8137, 1997.
26. Haber, D. A., Park, S., Maheswaran, S., Englert, C., Re, G. G.,
Hazen-Martin, D. J., Sens, D. A., and Garvin, A. J. WT-1 mediated
growth suppression of Wilms’ tumor cell expressing a WT-1 splicing
variant. Science (Washington DC), 262: 2057–2059, 1993.
27. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T.,
Miwa, H., Kita, K., Hiraoka, A., Massaoka, T., Nasu, K., Kyo, T., Dohy,
H., Nakauchi, H., Ishidate, T., Akiyama, T., and Kishimoto, T. WT-1 as
a new prognostic factor and a new marker for the detection of minimal
residual disease in acute leukemia. Blood, 84: 3071–3079, 1994.
28. Bergmann, B. L., Miething, C., Maurer, U., Brieger, J., Karakas, T.,
Weidmann, E., and Hoelzer, D. High levels of Wilms’ tumor gene
(wt-1) mRNA in acute myeloid leukemias are associated with a worse
long-term outcome. Blood, 90: 1217–1225, 1997.
29. Calogero, A., Cuomo, L., D’Onofrio, M., Grazia, U., Spinsanti, P.,
Mercola, D., Faggioni, A., Frati, L., Adamson, E. D., and Ragona, G.
Expression of EGR-1 correlates with the transformed phenotype and the
type of viral latency in EBV genome positive lymphoid cell lines.
Oncogene, 13: 2105–2112, 1996.
30. Huang, R-P., Fan, Y., Belle, I. D., Niemeyer, C., Gottardis, M. M.,
Mercola, D., and Adamson, E. D. Decreased Egr-1 expression in human,
mouse, and rat mammary cells and tissues correlates with tumor forma-
tion. Int. J. Cancer, 72: 102–109, 1997.
31. Levin, W. J., Press, M. F., Gaynor, R. B., Sukhatme, V. P., Boone,
T. C., Reissmann, P. T., Figlin, R. A., Holmes, E. C., Souza, L. M., and
Slamon, D. J. Expression patterns of immediate early transcription
factors in human non-small cell lung cancer. The Lung Cancer Study
Group. Oncogene, 11: 1261–1269, 1995.
32. Eid, M. A., Kumar, M. V., Iczkowski, K. A., Bostwick, D. G., and
Tindall, D. J. Expression of early growth response genes in human
prostate cancer. Cancer Res., 58: 2461–2468, 1998.
33. Mohn, K. L., Laz, T. M., Hsu, J., Melby, A. E., Bravo, R., and Taub,
R. The immediate-early growth response in regenerating liver- and
insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3
cells and identification of 41 novel immediate-early genes. Mol. Cell.
Biol., 11: 381–390, 1991.
34. Ahmed, M. M., Venkatasubbarao, K., Fruitwala, S. M., Muthukku-
mar, S., Wood, D. P., Sells, S. F., Mohiuddin, M., and Rangnekar, V. M.
EGR-1 induction is required for maximal radiosensitivity in A375–C6
melanoma cells. J. Biol. Chem., 271: 29231–29237, 1996.
35. Madden, S. L., Cook, D. M., Morris, J. F., Gashler, A., Sukhatme,
V. P., and Rauscher, F. J. Transcriptional repression mediated by the
WT-1 Wilms tumor gene product. Science (Washington DC), 253:
1550–1556, 1991.
4271Clinical Cancer Research
